188
Results-
Press ReleasePierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.Created on : - Last modified on :Castres (France), Geneva (Switzerland), 15 February 2024 – On February 20, International Ectodermal Dysplasias Awareness Day, Pierre Fabre Laboratories and the EspeRare Foundation will receive the EURORDIS Company Award for Patient Engagement 2024, at the EURORDIS Black Pearl Award Ceremony to be held in Brussels.
-
Press ReleaseKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesCreated on : - Last modified on :• Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.• The transaction is in furtherance of Kinnate’s previously announced pursuit of strategic alternatives.
-
Press ReleasePierre Fabre Laboratories presents the first global study on the “epidemiology of acne”Created on : - Last modified on :Published in February 2024 in the Journal of American Academy of Dermatology (JAAD), this study reveals the prevalence of acne worldwide in a completely new light.
-
Press ReleaseGlobal study on rosacea: 5% of the population affected, according to Pierre Fabre Laboratories.Created on : - Last modified on :Spotlight on rosacea, which affects 5% of the world population according to the first global epidemiological study of this dermatosis carried out by Pierre Fabre Laboratories.
-
Press ReleasePierre Fabre Laboratories Awarded Responsible Digital LabelCreated on : - Last modified on :May 16, 2024 – Pierre Fabre Laboratories has been awarded the highest level of the Digital Responsibility label for its commitment to a more environmentally and socially responsible digital industry. Overseen by Lucie, an agency specializing in CSR label management, the Digital Responsibility label (Label Numérique Responsable) is based on a set of guidelines developed by the Institute for Sustainable IT (INR) (Institut
-
Press Release" Green Bioplastics Project " wins 1st prize in the Maud Fontenoy FoundationCreated on : - Last modified on :Castres, June 13, 2024 - Pierre Fabre Laboratories are pleased to announce that their doctoral student Mariette Gibier has won 1st place in the Climate & Biodiversity trophies organized by the Maud Fontenoy Foundation, in partnership with the Forvia Foundation, in the Ocean & Innovation category for her Green Bioplastics project. An innovation co-developed by the R&D and PACKAGING teams of Pierre Fabre Laboratories, who support the work carried out by Mariette Gibier in collaboration with the biofoundry of the Sorbonne University Alliance.
-
Press ReleasePierre Fabre Laboratories receives the Galien International Prize for EBVALLO®Created on : - Last modified on :Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer
-
Press ReleasePierre Fabre Laboratoires signs a sponsorship agreement with the IHU healthAge In ToulouseCreated on : - Last modified on :Pierre Fabre Laboratories signs a sponsorship agreement with the IHU HealthAge in Toulouse to identify new biological mechanisms underlying skin aging. Toulouse, July 11, 2024 - Committed to understanding and addressing skin aging, Pierre Fabre Laboratories are extending their longstanding support to the University Hospital Center (CHU) of Toulouse and the teams led by Professor Bruno VELLAS, founding President of the Hospital-University Institute (IHU) HealthAge, through the signing of a five-year sponsorship agreement.
-
Press ReleasePierre Fabre & Scorpion Therapeutics announce new Phase I/II clinical trial for an innovative treatment in oncology.Created on : - Last modified on :Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer Driven by EGFR Exon 19 or 21 and Co-occurring C797S Mutations PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor (“EGFR”) inhibitor One of two EGFR programs being developed with Scorpion Therapeutics
-
Press ReleaseDosing of the first patient in the phase I/II trial evaluating PFL-002/VERT-002, a targeted therapy in oncologyCreated on : - Last modified on :PFL-002/VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action, acting as a degrader of c-MET, with the potential to be a best-in-class treatment for cancer driven by MET alterations
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.